par Marquette, Sarah 
;Amighi, Karim ;Goole, Jonathan ;Peerboom, Claude;Yates, Andrew;Denis, Laurence ;Langer, Ingrid
Référence International journal of pharmaceutics, 470, 1-2, page (41-50)
Publication Publié, 2014-08
;Amighi, Karim ;Goole, Jonathan ;Peerboom, Claude;Yates, Andrew;Denis, Laurence ;Langer, Ingrid Référence International journal of pharmaceutics, 470, 1-2, page (41-50)
Publication Publié, 2014-08
Article révisé par les pairs
| Résumé : | Antibodies (Abs) require the development of stable formulations and specific delivery strategies given their susceptibility to a variety of physical and chemical degradation pathways. In this study, the encapsulation of an antibody into polylactide-co-glycolide (PLGA) based microspheres was explored to obtain a controlled-release of the incorporated drug. In order to avoid stability issues, a solid-in-oil-in-water (s/o/w) method was preferred. The solid phase was made of anti-TNF alpha monoclonal antibody (MAb) spray-dried microparticles, and the PLGA microspheres were produced using two different polymers (i.e., Resomer® RG505 and Resomer® RG755S). The stability of the MAb incorporated into the microspheres was investigated under three conditions (5 ± 3 °C, 25 ± 2°C/60% RH and 40 ± 2°C/75% RH) for 12 weeks. During this stability study, it was demonstrated that the MAb loaded PLGA microspheres were stable when stored at 5 ± 3°C and that the Resomer® RG755S, composed of 75% (w/w) lactic acid as PLGA, was preferred to preserve the stability of the system. Storage at temperatures higher than 5°C led to antibody stability issues such as aggregation, fragmentation and loss of activity. The release profiles were also altered. Physical ageing of the system associated with changes in the glass transition temperature and enthalpy of relaxation was noticed during the storage of the MAb loaded PLGA microspheres. © 2014 Elsevier B.V. |
